Esperance A K Schaefer

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Anti-hepatitis C virus drugs in development
    Esperance A K Schaefer
    Massachusetts General Hospital, Department of Medicine, Gastrointestinal Unit, Boston, USA
    Gastroenterology 142:1340-1350.e1. 2012
  2. doi request reprint The impact of human gene polymorphisms on HCV infection and disease outcome
    Esperance A K Schaefer
    GI Unit, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Semin Liver Dis 31:375-86. 2011
  3. ncbi request reprint HCV and host lipids: an intimate connection
    Esperance A K Schaefer
    Massachusetts General Hospital, Harvard Medical School, GI Unit, Boston, Massachusetts
    Semin Liver Dis 33:358-68. 2013
  4. pmc The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling
    Kaku Goto
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108 8639, Japan Japan Society for the Promotion of Science, Tokyo 102 8472, Japan
    J Hepatol 59:942-8. 2013
  5. pmc Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase
    Lee F Peng
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Infect Dis 204:609-16. 2011

Collaborators

Detail Information

Publications5

  1. doi request reprint Anti-hepatitis C virus drugs in development
    Esperance A K Schaefer
    Massachusetts General Hospital, Department of Medicine, Gastrointestinal Unit, Boston, USA
    Gastroenterology 142:1340-1350.e1. 2012
    ..These new reagents against hepatitis C virus should lead to highly effective, well-tolerated, and likely interferon-sparing therapies in the next several years...
  2. doi request reprint The impact of human gene polymorphisms on HCV infection and disease outcome
    Esperance A K Schaefer
    GI Unit, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Semin Liver Dis 31:375-86. 2011
    ..Finally, PNPLA3 polymorphisms were initially described as predictors of nonalcoholic fatty liver disease, but have recently been associated with disease progression in HCV...
  3. ncbi request reprint HCV and host lipids: an intimate connection
    Esperance A K Schaefer
    Massachusetts General Hospital, Harvard Medical School, GI Unit, Boston, Massachusetts
    Semin Liver Dis 33:358-68. 2013
    ..The virus is then packaged alongside the cellular machinery for VLDL production. The complex interplay highlights pathways of hepatic steatosis and unveils drug targets for the treatment of HCV. ..
  4. pmc The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling
    Kaku Goto
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108 8639, Japan Japan Society for the Promotion of Science, Tokyo 102 8472, Japan
    J Hepatol 59:942-8. 2013
    ..The biological and therapeutic importance of host cellular cofactors for viral replication has been recently appreciated. Here we examined the roles of SNF1/AMP kinase-related kinase (SNARK) in HCV replication and pathogenesis...
  5. pmc Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase
    Lee F Peng
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Infect Dis 204:609-16. 2011
    ..The identification of more effective and better-tolerated agents for treating HCV is a high priority. We have reported elsewhere the discovery of the anti-HCV compound ceestatin using a high-throughput screen of a small molecule library...